Efficacy of first-line treatment options in advanced HER2-altered non-small cell lung cancer: A multi-center retrospective study

被引：0
|
作者：
Sun, H. [1 ,2 ]
Ge, Y. [1 ]
Wu, J. [1 ]
Sun, Y. [1 ]
Zhang, J. [1 ]
Cheng, Q. [1 ]
Wang, D. [1 ]
Wang, X. [1 ]
Li, J. [1 ]
Fu, X. [2 ]
Sun, H. [1 ,2 ]
Gao, A. [2 ]
机构：
[1] Shandong First Med Univ, Phase Clin Res Ctr 1, Canc Hosp, Jinan, Peoples R China
[2] Shandong First Med Univ, Dept Thorac Radiat Oncol, Canc Hosp, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2420
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1387P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study
    Chen, Jiayan
    Xu, Chunwei
    Wang, Qian
    Lv, Jiawen
    Lu, Wanjun
    Zhang, Yixue
    Yao, Yanwen
    Gu, Xiaoling
    Wu, Guannan
    Hao, Yue
    Pan, Weiwei
    Wang, Wenxian
    Zhang, Shirong
    Lv, Tangfeng
    Song, Yong
    Wang, Dong
    LUNG CANCER, 2023, 183
  • [2] A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study
    Lee, Chung-Shien
    Ahmed, Iman
    Miao, Emily
    Chung, Shirley
    Patel, Khilna
    Kohn, Nina
    Seetharamu, Nagashree
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (05) : 1140 - 1151
  • [3] Efficacy of first-line treatment options beyond RET-TKIs in advanced RET-rearranged non-small cell lung cancer: A multi-center real-world study
    Ge, Yihui
    Li, Juan
    Gong, Wenjing
    Wang, Jian
    Wei, Xiaojuan
    Liu, Jing
    Wang, Shuyun
    Wang, Leirong
    Sun, Haifeng
    Cheng, Qinglei
    Sun, Yanxin
    Dang, Qi
    Sun, Yuping
    Gao, Aiqin
    CANCER MEDICINE, 2024, 13 (02):
  • [4] Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study
    Yang, Yaning
    Yang, Guangjian
    Li, Weihua
    Hao, Xuezhi
    Zhang, Shuyang
    Ai, Xin
    Lei, Siyu
    Xu, Haiyan
    Wang, Yan
    THORACIC CANCER, 2023, 14 (33) : 3275 - 3281
  • [5] Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study
    Yang, Yaning
    Yang, Guangjian
    Wang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer
    Zhang, Shirong
    Wang, Wenxian
    Xu, Chunwei
    Zhang, Yongchang
    Cai, Xiuyu
    Wang, Qian
    Song, Zhengbo
    Li, Ziming
    Yu, Jinpu
    Zhong, Wenzhao
    Wang, Zhijie
    Liu, Jingjing
    Liu, Anwen
    Li, Wen
    Zhan, Ping
    Liu, Hongbing
    Lv, Tangfeng
    Miao, Liyun
    Min, Lingfeng
    Lin, Gen
    Huang, Long
    Yuan, Jingping
    Jiang, Zhansheng
    Pu, Xingxiang
    Rao, Chuangzhou
    Lv, Dongqing
    Yu, Zongyang
    Li, Xiaoyan
    Tang, Chuanhao
    Zhou, Chengzhi
    Zhang, Junping
    Guo, Hui
    Chu, Qian
    Meng, Rui
    Liu, Xuewen
    Wu, Jingxun
    Zhou, Jin
    Zhu, Zhengfei
    Pan, Weiwei
    Dong, Xiaowei
    Pang, Fei
    Wang, Kai
    Yao, Chao
    Lin, Guomin
    Li, Site
    Yang, Zhi
    Luo, Jiancheng
    Jia, Hongtao
    Nie, Xiuqing
    Wang, Liping
    THORACIC CANCER, 2023, 14 (01) : 91 - 104
  • [7] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Socinski, Mark A.
    DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
  • [8] Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis
    Zhao, Luqing
    Zhao, Zhiting
    Yan, Xiaoqi
    Wu, Fei
    Sun, Ning
    Guo, Renhong
    Yu, Shaorong
    Hu, Xiao
    Feng, Jifeng
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2024, 2024
  • [9] First-line treatment for non-small cell lung cancer
    Pinn, Stephen
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (01) : 10 - 10
  • [10] What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?
    Ricciuti, Biagio
    Awad, Mark M.
    CANCER JOURNAL, 2020, 26 (06): : 485 - 495
12345